Johnson & Johnson (XTER:JNJ) FFO


XTER:JNJ Johnson & Johnson XTER:JNJ
87 GF Score
Price €222.40
GF Value €166.43
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson FFO?

FFO (Funds from operations) only applies to REITs.

XTER:JNJ
87GF Score
Johnson & Johnson XTER:JNJ
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Johnson & Johnson (XTER:JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of €222.40 is trading 33.6% above its estimated GF Value™ of €166.43. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for XTER:JNJ:

  • FFO:
  • GF Value™: €166.43 vs. price of €222.40 (33.6% above fair value)
  • GF Score™: 87/100 with 7 warning signs

No single metric tells the full story. See the XTER:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
87GF Score

Get the complete analysis for XTER:JNJ

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€222.40
Price
€166.43
GF Value